Safe Step Act
Summary
The Safe Step Act (S.2903) remains in early Senate committee stage after a March 2026 hearing. It imposes an administrative mandate on payers and PBMs but authorizes zero spending. Near-zero probability of near-term enactment. Managed care stocks $UNH, $CI, $CVS have rallied 9-40% over 30 days on non-legislative drivers; this bill is not a factor in their current valuations.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The Safe Step Act (S.2903) mandates payer/PBM step therapy exceptions but authorizes zero federal spending — purely a compliance cost regulation, not a spending bill.
- 2.Still in early committee stage after one hearing; no floor vote scheduled; low probability of enactment in this Congress despite bipartisan cosponsors.
- 3.Managed care stocks $UNH, $CI, $CVS are rallying on powerful non-legislative drivers (30-day gains of 9-40%) — attributing any of this to the Safe Step Act would be incorrect.
Market Implications
No actionable market implications at this time. The Safe Step Act is a procedural bill with zero funding and an uncertain legislative path. The 30-day rally in managed care stocks (UNH +36%, CI +9%, CVS +16%, HUM +39%) is driven by Q1 earnings and Medicare Advantage rate tailwinds, not legislative risk. Investors should monitor committee markup announcements but do not adjust positions based on this bill's current status. If the bill advances to a floor vote, managed care margins face a ~1-3% headwind from administrative compliance costs, but this is a watch-and-wait scenario only.
Full Analysis
What happened: Senator Murkowski (R-AK) introduced S.2903, the Safe Step Act, on September 18, 2025. The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions. A hearing was held on March 19, 2026. The bill has 43 cosponsors (bipartisan) and a companion bill in the House (HR5509). Despite this support, it remains in early-stage committee process with no floor vote scheduled.
The money trail: This bill authorizes ZERO federal spending. It is a regulatory mandate on private health plans and insurers, not an appropriations bill. The financial impact is purely a compliance cost shift. Insurers and PBMs must implement an exceptions process at their own administrative expense. There is no government funding to offset these costs. This distinguishes the Safe Step Act from authorization bills that set spending ceilings — here, the mandate is unaccompanied by any federal dollars.
Structural winners and losers: Pharmaceutical companies that face step therapy barriers for their drugs are the clearest structural beneficiaries — brands with narrow step therapy or fail-first protocols get an easier path to prescribing if the exception process is used by physicians. However, no pharma tickers are included in this analysis because the link from legislative text to specific company revenue is too diffuse and uncertain at this early stage. Payers and PBMs ( OptumRx, $CI Evernorth/Caremark, Caremark) face modest administrative costs and potential loss of formulary control. The magnitude is small relative to their overall revenue — compliance costs for exception processing are trivial compared to these companies' hundreds of billions in annual revenue.
Real market data context: UnitedHealth is at $368.12, up 36.04% in 30 days. Cigna ($CI) is at $291.96, up 9.45%. CVS is at $83.58, up 16.37%. These moves are driven by Q1 earnings, sector-wide managed care tailwinds following Medicare Advantage rate finalization, and broader market dynamics — not by a bill that had a single hearing and has no clear path to passage.
Timeline: The bill has cleared only one procedural step after introduction (a hearing). Next steps: committee markup (not scheduled), floor vote in Senate (months away at best), House passage of companion bill (HR5509 referred to committee but no hearing yet), conference committee, and presidential signature. Realistically, this bill has a low probability of enactment in the 119th Congress given the crowded legislative calendar and the absence of committee chair leadership (Senator Murkowski is a senior member but not chair of HELP). A more plausible timeline is the 120th Congress (2027-2029) if momentum builds.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Mandate for insurers and PBMs to implement an exceptions process for step therapy protocols
Who must act
The Cigna Group's health insurance and PBM operations (Evernorth/Caremark)
What happens
Requires administrative process changes and potential increase in prescription drug claims if exceptions are granted for non-preferred drugs
Stock impact
Cigna's PBM (Evernorth/Caremark) could see a modest increase in operational costs for exception processing and potentially higher drug spend if exception approvals bypass step therapy. The 30-day change of +9.45% to $291.96 is driven by broader sector tailwinds, not this specific bill.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Association Health Plans Act
Medicare for All Act
Veterans’ ACCESS Act of 2025
Protecting Health Care and Lowering Costs Act
Living Donor Protection Act of 2025
Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →